Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 28, 2024 at 07:30 am EST
Share
Kiniksa Pharmaceuticals, Ltd. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 83.4 million compared to USD 61.88 million a year ago. Net income was USD 25.24 million compared to USD 4.46 million a year ago. Basic earnings per share from continuing operations was USD 0.36 compared to USD 0.06 a year ago. Diluted earnings per share from continuing operations was USD 0.35 compared to USD 0.06 a year ago.
For the full year, revenue was USD 270.26 million compared to USD 220.18 million a year ago. Net income was USD 14.08 million compared to USD 183.36 million a year ago. Basic earnings per share from continuing operations was USD 0.2 compared to USD 2.64 a year ago. Diluted earnings per share from continuing operations was USD 0.2 compared to USD 2.6 a year ago.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
KINIKSA PHARMACEUTICALS, LTD. 
